The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AAVP     (2S)-1- [[(10S,13S,16S,19S,22S)-16- (2...

Synonyms: AVPA, Mcppa-avp, CGP-25838, AC1L2XZW, Cgp 25838, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Mcppa-avp


High impact information on Mcppa-avp

  • Furthermore, infusion of d(CH2)5Tyr(Me)AVP to water-deprived animals (n = 6) to antagonize endogenous AVP resulted in systemic but not renal vasodilation, so that kidney blood flow rate fell (by approximately 30%), as did systemic-to-renal resistance ratio (by approximately 30%) [4].
  • In a first experiment, sexually inexperienced males received a single injection of AVP, saline, or d(CH2)5Tyr(Me)AVP in the lateral septum, after which their paternal responsiveness was recorded during a 10-min period [5].
  • Moreover, a well-characterized V1 vasopressin antagonist, [1-(beta-mercapto-beta, beta-cyclopentamethylene propionic acid),2-(O-methyl)tyrosine]Arg8-vasopressin [d(CH2)5Tyr(Me)AVP], competes with [3H]AVP binding with an IC50 of 0.17 microM [6].
  • Mean arterial pressure was reduced, and RSNA was increased by intravenous infusion of AVP antagonist d(CH2)5Tyr(Me)AVP (n = 8), whereas vertebral artery infusion of the antagonist (n = 6) did not change RSNA [7].
  • The V1 antagonist [d(CH2)5Tyr(Me)AVP] (10 micrograms/kg i.v.) had no effect on resting blood flow, but abolished the effect of vasopressin on blood flow to the choroid plexus [8].

Biological context of Mcppa-avp


Anatomical context of Mcppa-avp

  • In competition binding experiments with [3H]-SK&F 101926 using cell and liver membranes, guanosine 5'-(beta,gamma-imido)triphosphate did not significantly alter the affinity of the V1 antagonist d(CH2)5Tyr(Me)AVP, but the affinity of AVP was decreased [13].
  • However, when the vasopressin V1 antagonist, d(CH2)5Tyr(Me)AVP, was injected into the ventral septal area prior to interleukin-1, a fever was evoked which was significantly greater in magnitude and duration [14].
  • In a subsequent experiment we investigated the physiological impact of the stressor-induced release of AVP by administrating the AVP V1 receptor antagonist d(CH2)5Tyr(Me)AVP into the amygdala via inverse microdialysis [15].
  • Two days later, they were trained on 3 consecutive days (12 daily trials) to locate the hidden underwater platform in the Morris water maze (MWM) while the probes were perfused with either artificial cerebrospinal fluid (aCSF) or aCSF containing vasopressin or the V1 antagonist d(CH2)5Tyr(Me)AVP (AAVP) [16].
  • Distinct mechanisms of action of V1 antagonists OPC-21268 and [d(CH2)5Tyr(Me)AVP] in mesangial cells [17].

Associations of Mcppa-avp with other chemical compounds


Gene context of Mcppa-avp

  • The binding sites were specific and saturable: studies with the V1 AVP antagonist d(CH2)5Tyr(Me)AVP and the V2 agonist 1-deamino-8-D-AVP indicated that the AVP receptor was V1 in specificity [23].
  • The selective vascular (V1) receptor antagonist [d(CH2)5 1Tyr(Me)2]AVP (SK&F 100273) shifted the concentration-response curves for AVP-induced vascular contraction to the right in a parallel manner (KB = 2.23 X 10(-9) M) [24].
  • The enhanced cardiovascular effects of AVP in OT-pretreated animals were dose dependent, blocked by the V1 antagonist d(CH2)5Tyr(Me)AVP, not evoked by OT alone, and occurred in the absence of changes in basal (nonstimulated) MAP and HR [25].
  • Displacement of 3H-AVP binding with high affinity by unlabelled AVP, LVP and the V1 antagonist, d(CH2)5Tyr(Me)AVP, indicated that the Leydig cell AVP receptor is of the V1 type [26].
  • The potentiation by vasopressin was reduced by the antagonist of vasopressin V1 receptors d(CH2)5Tyr(Me)AVP (10(-7) M), but not by the vasopressin V2 receptor antagonist d(CH2)5D-Ile2, Ile4AVP (10(-7) M) [27].

Analytical, diagnostic and therapeutic context of Mcppa-avp


  1. Baroreceptor reflex modulation by vasopressin microinjected into the nucleus tractus solitarii of conscious rats. Michelini, L.C., Bonagamba, L.G. Hypertension (1988) [Pubmed]
  2. Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Nicod, P., Waeber, B., Bussien, J.P., Goy, J.J., Turini, G., Nussberger, J., Hofbauer, K.G., Brunner, H.R. Am. J. Cardiol. (1985) [Pubmed]
  3. Vasopressin potentiates ventricular and arterial reflexes in the conscious nonhuman primate. Barazanji, M.W., Cornish, K.G. Am. J. Physiol. (1989) [Pubmed]
  4. Mechanism of preservation of glomerular perfusion and filtration during acute extracellular fluid volume depletion. Importance of intrarenal vasopressin-prostaglandin interaction for protecting kidneys from constrictor action of vasopressin. Yared, A., Kon, V., Ichikawa, I. J. Clin. Invest. (1985) [Pubmed]
  5. Role of septal vasopressin innervation in paternal behavior in prairie voles (Microtus ochrogaster). Wang, Z., Ferris, C.F., De Vries, G.J. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  6. Identification and characterization of a vasopressin isoreceptor in porcine seminal vesicles. Maggi, M., Kassis, S., Malozowski, S., Guardabasso, V., Rodbard, D. Proc. Natl. Acad. Sci. U.S.A. (1986) [Pubmed]
  7. Central and peripheral vasopressin interact differently with sympathetic nervous system and renin-angiotensin system in renal hypertensive rabbits. Kumagai, H., Suzuki, H., Ichikawa, M., Matsumura, Y., Jimbo, M., Ryuzaki, M., Saruta, T. Circ. Res. (1993) [Pubmed]
  8. Humoral regulation of blood flow to choroid plexus: role of arginine vasopressin. Faraci, F.M., Mayhan, W.G., Farrell, W.J., Heistad, D.D. Circ. Res. (1988) [Pubmed]
  9. Development of high sodium renal hypertension during chronic blockade of the vascular effects of vasopressin. Hinojosa, C., Haywood, J.R. J. Pharmacol. Exp. Ther. (1986) [Pubmed]
  10. Mechanism of the depressor action of LY171555, a selective dopamine D2 receptor agonist, in the anesthetized rat. Nagahama, S., Chen, Y.F., Lindheimer, M.D., Oparil, S. J. Pharmacol. Exp. Ther. (1986) [Pubmed]
  11. Effects of arginine vasopressin on protein phosphorylation in rat hippocampal synaptic membranes. Hinko, A., Pearlmutter, A.F. J. Neurosci. Res. (1987) [Pubmed]
  12. Endogenous vasopressin modulates the baroreflex sensitivity in rats. Imai, Y., Nolan, P.L., Johnston, C.I. Clin. Exp. Pharmacol. Physiol. (1983) [Pubmed]
  13. A novel radiolabeled vasopressin antagonist: [3H-Phe]-desGlyd(CH2)5D-Tyr(Et)VAVP, [3H]-SK&F 101926. Stassen, F.L., Heckman, G., Schmidt, D., Nambi, P., Aiyar, N., Landvatter, S., Crooke, S.T. Mol. Pharmacol. (1987) [Pubmed]
  14. Evidence supporting a role for endogenous vasopressin in fever suppression in the rat. Cooper, K.E., Naylor, A.M., Veale, W.L. J. Physiol. (Lond.) (1987) [Pubmed]
  15. Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats. Ebner, K., Wotjak, C.T., Landgraf, R., Engelmann, M. Eur. J. Neurosci. (2002) [Pubmed]
  16. Vasopressin administration via microdialysis into the septum interferes with the acquisition of spatial memory in rats. Engelmann, M., Bures, J., Landgraf, R. Neurosci. Lett. (1992) [Pubmed]
  17. Distinct mechanisms of action of V1 antagonists OPC-21268 and [d(CH2)5Tyr(Me)AVP] in mesangial cells. Jamil, K.M., Watanabe, T., Nakao, A., Okuda, T., Kurokawa, K. Biochem. Biophys. Res. Commun. (1993) [Pubmed]
  18. Involvement of vasopressin in the cardiovascular effects of intracerebroventricularly administered alpha 1-adrenoceptor agonists in the conscious rat. Hiwatari, M., Johnston, C.I. J. Hypertens. (1985) [Pubmed]
  19. Mechanism of the pressor action of LY171555, a specific dopamine D2 receptor agonist, in the conscious rat. Nagahama, S., Chen, Y.F., Lindheimer, M.D., Oparil, S. J. Pharmacol. Exp. Ther. (1986) [Pubmed]
  20. Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3T3 cells. Serradeil-Le Gal, C., Bourrié, B., Raufaste, D., Carayon, P., Garcia, C., Maffrand, J.P., Le Fur, G., Casellas, P. Biochem. Pharmacol. (1994) [Pubmed]
  21. New insights into neuropeptide modulation of aggression: field studies of arginine vasotocin in a territorial tropical damselfish. Santangelo, N., Bass, A.H. Proc. Biol. Sci. (2006) [Pubmed]
  22. Hemodynamic and pharmacological evaluation of the vasodilator and vasoconstrictor effects of endothelin-1 in rats. Le Monnier de Gouville, A.C., Mondot, S., Lippton, H., Hyman, A., Cavero, I. J. Pharmacol. Exp. Ther. (1990) [Pubmed]
  23. Arginine vasopressin and oxytocin in the bovine adrenal gland. Nussey, S.S., Prysor-Jones, R.A., Taylor, A., Ang, V.T., Jenkins, J.S. J. Endocrinol. (1987) [Pubmed]
  24. Human vascular vasopressin receptors: analysis with selective vasopressin receptor antagonists. Ohlstein, E.H., Berkowitz, B.A. J. Pharmacol. Exp. Ther. (1986) [Pubmed]
  25. Enhanced pressor responses to ICV vasopressin after pretreatment with oxytocin. Poulin, P., Komulainen, A., Takahashi, Y., Pittman, Q.J. Am. J. Physiol. (1994) [Pubmed]
  26. Identification and characterization of arginine vasopressin receptors in the clonal murine Leydig-derived TM3 cell line. Maggi, M., Morris, P.L., Kassis, S., Rodbard, D. Int. J. Androl. (1989) [Pubmed]
  27. Impaired potentiation by endothelin-1 and vasopressin of sympathetic contraction in tail artery from hypertensive rats. García-Villalón, A.L., Monge, L., Fernández, N., Sánchez, M.A., Martínez, M.A., Gómez, B., Diéguez, G. Cardiovasc. Res. (2000) [Pubmed]
  28. Vasopressin released within the septal brain area during swim stress modulates the behavioural stress response in rats. Ebner, K., Wotjak, C.T., Holsboer, F., Landgraf, R., Engelmann, M. Eur. J. Neurosci. (1999) [Pubmed]
  29. Inhibition of vasopressin-stimulated flank marking behavior by V1-receptor antagonists. Ferris, C.F., Singer, E.A., Meenan, D.M., Albers, H.E. Eur. J. Pharmacol. (1988) [Pubmed]
  30. Haemodynamic and humoral consequences of chronic infusion of vasopressin in conscious rats. Tsuchihashi, T., Takata, Y., Nakao, Y., Tominaga, M., Takishita, S., Kobayashi, K., Abe, I., Fujishima, M. Clin. Exp. Pharmacol. Physiol. (1993) [Pubmed]
  31. Haemodynamic role of vasopressin released during Finnish sauna. Bussien, J.P., Gaillard, R.C., Nussberger, J., Waeber, B., Hofbauer, K.G., Turnill, D., Brögger, R., Brunner, H.R. Acta Endocrinol. (1986) [Pubmed]
WikiGenes - Universities